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Abstract
Androgen receptor (AR) signaling pathway remains the foremost target of novel therapeutics for castration-resistant
prostate cancer (CRPC). However, the expression of constitutively active AR variants lacking the carboxy-terminal region in
CRPC may lead to therapy inefficacy. These AR variants are supposed to support PCa cell growth in an androgen-depleted
environment, but their mode of action still remains unresolved. Moreover, recent studies indicate that constitutively active
AR variants are expressed in primary prostate tumors and may contribute to tumor progression. The aim of this study was to
investigate the impact of constitutively active AR variants on the expression of tumor progression markers. N-cadherin
expression was analyzed in LNCaP cells overexpressing the wild type AR or a constitutively active AR variant by qRT-PCR,
Western blot and immunofluorescence. We showed here for the first time that N-cadherin expression was increased in the
presence of constitutively active AR variants. These results were confirmed in C4-2B cells overexpressing these AR variants.
Although N-cadherin expression is often associated with a downregulation of E-cadherin, this phenomenon was not
observed in our model. Nevertheless, in addition to the increased expression of N-cadherin, an upregulation of other
mesenchymal markers expression such as VIMENTIN, SNAIL and ZEB1 was observed in the presence of constitutively active
variants. In conclusion, our findings highlight novel consequences of constitutively active AR variants on the regulation of
mesenchymal markers in prostate cancer.
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Introduction
Prostate cancer (PCa) is the most common cancer in men over
50 years of age and the second cause of male mortality due to
cancer in Europe. Androgens signaling plays a key role in PCa
cells proliferation or survival [1], and androgen withdrawal
remains the main treatment for local recurrence and androgen-
dependent metastatic PCa. However, the benefit of this therapy is
transient and all tumors ultimately recur as castration-resistant
PCa (CRPC).
Genetic and splicing events affecting the androgen receptor
(AR) gene have been linked to CRPC. Constitutively active AR
variants, lacking the carboxy-terminal region that encompasses the
ligand binding domain and the activation function 2, might
contribute to the progression of PCa into castration resistance.
These constitutively active AR variants result from premature stop
codons due to nonsense mutations as reported for the ARQ640X
[2,3,4,5] or from alternative splicing with the retention of a cryptic
exonic sequence as described for AR-V7 [4,6,7,8,9,10].
The role of constitutively active AR variants in CRPC has been
shown in many studies [7,8,11,12]. The expression of these
truncated AR variants is increased by a 20-fold in CRPC
compared with localized PCa [9], and is correlated with the
capacity of PCa cells to grow in vitro and in vivo in the absence of
androgen [7]. However, the exact molecular mechanisms leading
to their activation and their mode of action in PCa and CRPC
remain unclear.
Recent studies suggest that constitutively active AR variants
could play a role in tumor progression. Indeed, although these
constitutively active AR variants are already expressed in primary
prostate tumors, their expression is all the more expressed in bone
metastasis [8]. Furthermore, their expression is associated with an
increase of NFAT (Nuclear factor of activated T-cell) and AP-1
(Activator Protein-1) activity, two transcription factors involved in
cell proliferation, migration and survival [13].
N-cadherin, which belongs to cadherin superfamily, is located at
adherens junctions in nervous, endothelial or mesenchymal cells
and is involved in tumor progression [14,15]. Indeed, N-cadherin
expression is increased in most cancers and promotes tumor cells
migration, invasion and survival [14]. Increased N-cadherin
expression is also associated with epithelial-mesenchymal transi-
tion (EMT), a phenomenon characterized by a decrease of
epithelial markers such as E-cadherin and an increase of
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mesenchymal markers such as Vimentin or N-cadherin
[16,17,18,19]. These molecular and cellular modifications play
an important role in tumor cells dissemination at secondary sites
[20,21].
More recently, studies have shown that castration-resistant PCa
is associated with an upregulation of N-cadherin expression in
cellular models as well as PCa xenografts and clinical samples of
CRPC [22,23,24]. Moreover, monoclonal antibodies against N-
cadherin have been shown to delay the emergence of castration
resistance and to reduce the growth of CRPC xenografts [23].
Taken together, these data show that there is a correlation
between N-cadherin expression and resistance to castration.
Nevertheless, molecular mechanisms whereby N-cadherin expres-
sion is increased in CRPC remain unknown.
The aim of this work was to show a possible link between the
presence of constitutively active AR variants and the expression of
tumor progression markers. More particularly, we focused on the
impact of constitutively active AR variants on the expression of N-
cadherin and other mesenchymal markers. In the present study,
we have shown that N-CADHERIN as well as VIMENTIN, SNAIL
and ZEB1 are upregulated in the presence of constitutively active
AR variants in PCa.
Materials and Methods
Cell culture
The human prostate carcinoma LNCaP cell line, clone FGC
and the 22Rv1 cell line (ECACC, Salisbury, United Kingdom) was
maintained in RPMI-1640 complete medium containing 10%
fetal calf serum (FCS), 10 mM HEPES, 2 mM L-glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin (Sigma-Aldrich,
France) and 1mM sodium pyruvate (Invitrogen, Fisher Scientific,
France).
C4-2B cell line (ViroMed Laboratories, Minnetonka, MN,
USA) was maintained in DMEM medium supplemented with
20% Ham’s F12, 10% FCS, 100 U/mL penicillin, 100 mg/mL
streptomycin, 5 mg/mL insulin, 13.65 pg/mL triiodo-thyronine,
4.4 mg/mL apo-transferrin human, 0.244 mg/mL d-biotin and
12.5 mg/mL adenine (Sigma-Aldrich, France).
Plasmids and transfection
For immunofluorescence experiments, the wild type androgen
receptor (AR) (AR-WT) and the constitutively active AR Q640X
and AR Q670X [25] variants were linked to EGFP as previously
described [2,3]. For gene expression analysis and Western-blot,
pE-ARWT, pE-ARQ640X and pE-AR-V7 plasmids were con-
structed by inserting the corresponding AR cDNA between the
NheI and BamHI sites in pEGFP-C3.
For transfections, the JetPEITM transfection reagent (Polyplus
Transfection, Ozyme, France) was used according to the
manufacturer’s protocol. LNCaP cells were seeded in 10 cm
dishes at 16106 cells/dish or in 6-wells plate at 26105/well. Three
days later, the medium was changed and cells were transfected
with 10 mg of the indicated plasmid using 20 ml of JetPEI
transfection reagent for 10 cm dishes or with 3 mg of plasmid
using 6 ml of JetPEI for 6-wells plate. Medium was changed 48 h
after and cells were incubated up to 9 days according to the
experiments. The medium was changed every two days and for
incubations beyond 4 post-transfection days, cells were incubated
in the presence of 400 mg/mL geneticin (Invitrogen, France).
Impact of androgens on N-cadherin expression
LNCaP cells were seeded in 6-wells plate in complete medium
and transfected as previously described. Twenty four hours later,
medium was changed to phenol red free RPMI-1640 supplement-
ed with 5% dextran-coated charcoal-stripped FCS (DCC-FCS)
and with the indicated concentration of dihydrotestosterone
(DHT) (Sigma-Aldrich, France) or vehicle (ethanol).
For experiment with MDV3100, transfected LNCaP cells were
incubated in RPMI-1640 supplemented with 5% DCC-FCS
containing the indicated DHT dose and 100 nM MDV3100
(Enzalutamide, Selleck Chemicals, Euromedex, France) or vehicle
(dimethyl sulfoxide, DMSO). To confirm the effects of androgens
on N-cadherin expression, 22Rv1 cells were grown in RPMI-1640
with 100 nM or 1 mM MDV3100, or DMSO.
Cell Sorting
LNCaP cells were seeded in 10cm dishes at 16106 cells/dish
and were transfected with pEGFP-ARWT or pEGFP-ARQ640X.
Four days after transfection, cells were trypsinized and sorted
thanks to the green fluorescence (EGFP) with a BD FACSAria-II
cell sorter (BD Biosciences, Le Pont de Claix, France). Total RNA
was extracted from EGFP negative (non-transfected) and EGFP
positive (transfected) cells and was used to analyze gene expression
by qRT-PCR.
Quantitative real-time PCR
Total cellular RNA was extracted from cell lines using
NucleoSpinH RNA II assay (Macherey-Nagel, France) according
to the manufacturer’s procedure. RNA concentrations and purity
were quantified measuring the absorbance at 260 nm and 280 nm
(GeneQuant pro, GE Healthcare, France). The reverse transcrip-
tion was performed from 400 ng or 1 mg RNA using RT
Omniscript assay (Qiagen, Courtaboeuf, France). RNA were
diluted into 13 mL and denatured at 65uC during 5 minutes. A
7 mL reaction mix containing 16RT template, 0.5 mM of each
dNTP, 1 mM oligo dT, 10U RNase inhibitor and 4U Omniscript
Reverse Transcriptase was added and the reaction was incubated
1 h at 37uC. The reaction was stopped by heating to 93uC for
5 minutes. N-CADHERIN, E-CADHERIN, VIMENTIN, SNAIL,
TWIST1, and ZEB1 mRNA levels were quantified using real-time
PCR with LightCycler 480 (Roche Applied Science, Meylan,
France). For PCR reactions, 5 mL LightCyclerH 480 SYBR Green
I Master (Roche, Molecular Diagnostics, Mannheim, Germany)
and 1 mL specific primers (Table 1) (Qiagen, QuantiTect Primers,
Courtaboeuf, France) were mixed with 4 mL of 1:5 cDNA dilution.
Results were normalized using housekeeping gene b-ACTIN or
PBGD (Porphobilinogen deaminase) (Qiagen, QuantiTect Primer).
Amplification specificity was verified by analyzing melting curve
and by electrophoresis migration. All experiments were realized in
triplicate and repeated 3 times. Relative quantification was used to
determinate fold change in expression level by the DDCt method.
Each value is expressed as the mean DDCt 6 SEM. Results were
analyzed with Student t test and p-value ,0.05 was considered
significant.
Western Blot
Cells were lysed in buffer containing 10 mM Tris-HCl pH7,
140 mM NaCl, 3 mM MgCl2, 0.56Igepal, 5 mM DTT, 16
phosphatase inhibitor, and 16 protease inhibitor. Protein
concentration for each sample was quantified using BCA Protein
Assay (Pierce Biotechnology, Inc., Rockford, IL, USA) according
to the manufacturer’s procedure. A quantity of 15 mg to 100 mg of
total proteins was loaded on 7,5% SDS-PAGE. After migration
and transfer to nitrocellulose membrane, membranes were
saturated with PBS/0.1%Tween/2%ECL and incubated at 4uC
overnight with 0.1 mg/mL mouse monoclonal anti N-cadherin
(catalog no. 610920, BD Biosciences, France) or 1 mg/mL mouse
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monoclonal anti AR (catalog no. 554225, BD Biosciences, France)
antibody. b-actin (0.2 mg/mL) (catalog no. sc-47778, Tebu-bio,
France) was used as internal control. After washes, immunocom-
plexes were detected with 0.2 mg/mL HRP-conjugated goat anti
mouse (catalog no. sc-2005, Tebu-bio, France), or 0.5 mg/mL rat
anti mouse IgG2a secondary antibodies (catalog no. 553391, BD
Biosciences, France), and finally revealed by chemiluminescence
(ImmobilonTM Western, Millipore, Molsheim, France).
Immunofluorescence Staining
Lab-Tek II chamber slides (2 wells) were coated with LNCaP
medium for two hours and 16105 LNCaP cells/well were seeded.
LNCaP cells were transfected with 2 mg of pEGFP-WT, pEGFP-
ARQ640X or pEGFP-ARQ670X 3 days later and incubated for
4 days. LNCaP cells were rinsed in PBS and fixed with 2%
paraformaldehyde. Cells were blocked and permeabilized by 0.1%
Triton/1% Bovine Serum Albumin (BSA)/PBS for 30 min at
room temperature. Cultures were incubated with 2.5 mg/mL anti
N-cadherin mouse monoclonal antibody (catalog no. 610920, BD
Biosciences, France) or isotypic antibody (Sigma-Aldrich, Saint-
Quentin Fallavier, France) at 4uC overnight. After washing in
PBS, LNCaP cells were incubated with 2 mg/mL Alexa Fluor 568-
conjugated goat anti mouse (Invitrogen, Fisher Scientific, France)
for 1 h and nuclei were stained with 0.1 mg/mL DAPI solution for
20 min at 30uC. Images were captured with the Leica LAS
AF6000 fluorescence microscope using LAS AF software (Leica).
Results
Constitutively active androgen receptor variants
upregulate N-cadherin expression in prostate cancer cells
Constitutively active AR variants have been associated with
CRPC. Moreover, some studies showed that CRPC is also
associated with an upregulation of N-cadherin expression [22,23].
We investigated whether constitutively active AR variants
upregulate N-cadherin expression in PCa cells. N-CADHERIN
mRNA level was determined by qRT-PCR in LNCaP cells
overexpressing the constitutively active AR Q640X or AR-V7, or
the AR-WT as control (Figure 1). N-CADHERIN expression
remained unchanged in LNCaP cells overexpressing AR-WT
compared with controls. Interestingly, N-CADHERIN expression
was increased by a 8,000-fold in the presence of ARQ640X and
AR-V7 (Figure 1A-B). These data were confirmed in C4-2B cells
(Figure S1) and at the protein level in LNCaP cells (Figure 1C). In
addition, a time course experiment revealed that N-cadherin
protein levels were consistently increased from day-3 after LNCaP
cells transfection with ARQ640X (Figure 1D).
To confirm these data from transient transfection, a cell-sorting
analysis was performed after LNCaP transfection to demonstrate
that N-cadherin expression was restricted to cells expressing a
constitutively active AR. N-CADHERIN expression was analyzed
in EGFP negative (non-transfected cells) or EGFP positive
(transfected cells) fractions by qRT-PCR. Consistent with above
results, N-CADHERIN expression was undetectable in both EGFP-
negative and positive fractions following LNCaP transfection with
pEGFP-ARWT. However, upon transfection with pEGFP-
ARQ640X, N-CADHERIN expression was increased in EGFP
positive cells overexpressing the constitutively active AR, but not
in the EGFP negative fraction (Figures 2A–B). These results were
further confirmed by immunofluorescence analysis showing an N-
cadherin labeling exclusively in EGFP positive cells expressing a
constitutively active AR variant (Figure 2C).
Taken together, these data strongly suggest that constitutively
active AR variants upregulate N-cadherin expression in PCa cells.
Androgens negatively regulate N-cadherin expression
induced by constitutively active androgen receptor
variants
A recent study reported that constitutively active AR variants
might require a full-length AR (AR-FL) to activate endogenous
target genes. To explore the effect of the endogenous AR-FL
present in LNCaP cells on the ability of constitutively active AR
variants to induce N-cadherin expression, LNCaP cells overex-
pressing AR-WT or a constitutively androgen variant were
incubated in the presence of 100 nM DHT or vehicle, and N-
cadherin expression was analyzed by qRT-PCR. In accordance
with our previous results, no N-cadherin expression was observed
in cells overexpressing AR-WT. Interestingly, a 1.4-fold decrease
in N-cadherin expression level was observed when cells overex-
pressing AR Q640X or AR-V7 were cultured in the presence of
100 nM DHT compared to vehicle (Figure 3A). In addition, this
androgen-mediated N-cadherin repression was dose-dependent
(Figure 3B). These results suggest that constitutively active
androgen receptor variants do not require AR-FL to up-regulate
N-cadherin expression. However, DHT-activated AR-FL seems to
antagonize effects of constitutively active androgen receptor
variants on N-cadherin expression (Figure 3C). To verify this
hypothesis, the novel anti-androgen MDV3100 was used to inhibit
DHT-activated AR-FL in transfected LNCaP cells. As expected, a
further significant increase of N-cadherin expression was observed
in LNCaP cells overexpressing AR variants in the presence of
Table 1. List of primers used in qRT-PCR experiments.
Genbank QuantiTect reference
Hybridization temperature
(uC) Amplicon length (bp) Amplified exons
b-ACTIN (ACTB) QT01680476 55/60 104 NA
E-CADHERIN (CDH1) QT00080143 55 84 5/6
N-CADHERIN (CDH2) QT00063196 60 102 14/15
PBGD (HMBS) QT00014462 55 107 7/8/9
TWIST1 QT00011956 55 127 1/2
SNAIL (SNAI1) QT00010010 60 131 2/3
VIMENTIN QT00095795 60 94 2/3
ZEB1 QT01888446 58 105 2/3/4
doi:10.1371/journal.pone.0063466.t001
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100 nM MDV3100 (Figure 3D). These results were also
confirmed in castration-resistant 22Rv1 cells, known to express
both AR-FL and constitutively active AR variants. A 2-fold
increase in N-cadherin mRNA level was observed when 22Rv1
cells were cultured for 4 days in the presence 100 nM and 1 mM
of the anti-androgen MDV3100 (Figure S2).
All together, these data suggest that DHT-activated AR-FL
could compete with constitutively active androgen receptor for
regulating N-cadherin expression.
Constitutively active androgen receptor variants are
associated with the expression of mesenchymal markers
It is widely known that in tumor cells, the expression of
mesenchymal markers is associated with a down-regulation of
epithelial markers. We hypothesized that the upregulation of N-
cadherin expression observed in the presence of constitutively
active AR variants is accompanied by a decreased expression of E-
cadherin. To test this hypothesis, we analyzed E-cadherin
expression in LNCaP transfected with ARQ640X, AR-V7 or
the wild type AR expression plasmid, or the empty plasmid as
control. E-CADHERIN mRNA levels in LNCaP cells upon
transfection with ARQ640X or AR-V7 expression plasmid did
not show any significant difference compared with controls
(Figure 4A). These results were further confirmed by Western
blot analysis (data not shown), suggesting that the expression of
constitutively active AR variants in PCa is associated with a
marked increase in N-cadherin expression, but is not correlated
with a down-regulation of E-cadherin.
We also investigated whether constitutively active AR expres-
sion in PCa cells is associated with other mesenchymal markers.
Expression levels of VIMENTIN and transcription factors
TWIST1, ZEB1 and SNAIL were determined by qRT-PCR at
day-9 after LNCaP cells transfection with ARQ640X or AR-V7
expression plasmid, the wild type AR plasmid or the empty vector
as controls (Figure 4B–E). VIMENTIN expression was increased by
a 2.5 and 1.5-fold in LNCaP cells overexpressing ARQ640X and
AR-V7 when compared with controls respectively (Figure 4B).
Although Twist1 is known to induce N-CADHERIN expression
in PCa, no significant difference in the mRNA levels of TWIST1
was observed (Figure 4C). However, constitutively active AR
variants led to a statistically significant increase of SNAIL and
ZEB1 mRNA levels (Figure 4D, E). ZEB1 upregulation was also
confirmed at the protein level (Figure 4F).
Discussion
The AR signaling is very important for proliferation and
survival of prostate cancer cells. The AR pathway remains
activated during the progression of PCa towards a castration-
Figure 1. N-cadherin expression is upregulated in the presence of constitutively active androgen receptor variants. A). N-cadherin
expression was assessed by qRT-PCR in LNCaP cells overexpressing the constitutively active AR Q640X or AR-V7, or the AR-WT and in cells transfected
with the empty plasmid (C3). Cells were grown in complete medium for 9 days after transfection. Parental LNCaP cells were used as control. y-Axis
represents the relative fold change compared with control (parental LNCaP cells). b-ACTIN was used as the endogenous normalization control.
Relative expression is presented as the mean6 SEM from three independent experiments. Each sample is compared one by one by two tail unpaired
t test. NS: Not significant * P,0.05, **P,0.01 and ***P,0.001. B). Western Blot showing AR expression in transfected and non transfected LNCaP cells.
C). Immunoblot analysis of N-cadherin expression in transfected LNCaP cells 4 and 9 days after transfection. D). Kinetic analysis of N-cadherin
expression by Western Blot in LNCaP cells overexpressing AR Q640X from 2 to 9 days after transfection. b-actin was used as loading control.
doi:10.1371/journal.pone.0063466.g001
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resistant disease and the emergence of constitutively active AR
variants lacking the ligand-binding domain is now considered as a
major event in CRPC. In spite of some studies suggest that
constitutively active AR variants have an impact on tumor
progression, their function remains so far unresolved.
Figure 2. N-cadherin upregulation was restricted to LNCaP cells expressing constitutively active androgen receptor variants. LNCaP
cells were transiently transfected with pEGFP-ARWT or pEGFP-ARQ640X plasmid and were sorted 4 days after. A). N-CADHERIN expression was
analyzed by qRT-PCR in EGFP positive (transfected) and EGFP negative (non-transfected) fractions. B). Androgen receptor (AR) level was analyzed by
Western Blot to verify the purity of each fraction after cell sorting. C). Immunofluorescence analysis of N-cadherin (red fluorescence) expression in
LNCaP cells transfected with EGFP-tagged (green fluorescence) AR-WT, AR Q640X or AR Q670X expression plasmid. Magnification:620.
doi:10.1371/journal.pone.0063466.g002
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In this study, we have shown that N-cadherin is upregulated in
LNCaP cells expressing constitutively active AR variants, but not
in LNCaP cells overexpressing a full-length AR. These data
suggest for the first time that constitutively active AR variants can
induce N-cadherin expression. This finding should be connected
to recent studies reporting a correlation between CRPC and N-
cadherin upregulation [22,23,24]. Consistent with these studies,
our data suggest that constitutively active AR variants signaling
could be a mechanism leading to N-cadherin expression in CRPC.
These findings again highlight the link between AR signaling
pathway and N-cadherin expression. Recent studies suggest that
AR negatively regulates N-cadherin expression [22,23]. Indeed,
N-cadherin upregulation is associated with a decreased expression
of AR in castration-resistant PCa xenografts [23]. Furthermore,
the upregulation of N-cadherin observed in the castration-resistant
LNCaP-19 cells can be reversed in the presence of androgens
[22,26,27]. In accordance with these data, we have shown that
androgens were associated with a decreased N-cadherin expres-
sion in our model overexpressing a constitutively active androgen
receptor variant. These results suggest that AR-FL and constitu-
tively active AR variants could act differently (Figure 3C). For
example, DHT-stimulated AR-FL might recruit co-repressors and,
in turn, represses N-CADHERIN expression. Besides, constitutively
active AR variants lacking of carboxy-terminal region might
behave differently and induce N-CADHERIN expression. Further-
more, AR-FL and constitutively active AR variants could compete
with each other for regulating N-cadherin expression. Consistent
with this hypothesis, N-CADHERIN gene contains a cluster of
androgen response elements (ARE) repeats in intron 1 [28].
However, constitutively active AR variants could also indirectly
control N-CADHERIN expression. For example, in prostate
cancer, N-CADHERIN expression was associated with a nuclear
translocation of Twist1 [29]. Although our data showed no
significant difference in TWIST1 mRNA levels, constitutively
active AR variants might enhance nuclear translocation of Twist1,
which could in turn induce N-CADHERIN expression after binding
to the E-box within the first intron of N-CADHERIN.
Figure 3. Androgens abrogate N-cadherin upregulation induced by constitutively active androgen receptor variants in LNCaP cells.
A). LNCaP cells were grown in RPMI-1640 containing 5% DCC-FCS and 100 nM of DHT or vehicle (EtOH). N-cadherin expression was analyzed by qRT-
PCR in LNCaP cells 4 days after transfection with AR-WT or the constitutively active AR Q640X or AR-V7 expression plasmid. B). N-cadherin expression
level in LNCaP cells was investigated by qRT-PCR 4 days after transfection with AR Q640X expression plasmid in the presence of different DHT
concentrations (10 nM, 25 nM and 50 nM) or vehicle. C). N-cadherin expression induced by constitutively active AR variants (AR variants) was
negatively regulated when LNCaP cells were grown in the presence of DHT. We hypothesize that endogenous AR-FL present in LNCaP cells and AR
variants could act differently. In this model, DHT-stimulated endogenous AR-FL represses N-cadherin expression whereas AR variants upregulate its
expression. D). LNCaP cells overexpressing AR-WT, AR Q640X and AR-V7 were cultured in DCC-FCS medium supplemented with 100 nM of DHT and
in the presence of 100 nM of MDV3100 or DMSO as control during 3 days. N-cadherin expression was analyzed by qRT-PCR 4 days after transfection,
and was normalized to b-ACTIN. The DDCt method was used to calculate relative expression and each value was reported as the mean of DDCt 6
SEM. NS: Not Significant * P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0063466.g003
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These hypotheses deserve to be studied in further studies to
understand how constitutively active AR variants regulate N-
CADHERIN expression.
In this study, we have also shown that constitutively active AR
variants were associated with an increased expression of mesen-
chymal markers as VIMENTIN, SNAIL and ZEB1. These results
are consistent with a recent study, which showed an increase of
mesenchymal markers in tumors from patients treated with
androgen deprivation therapy [24]. Taken together, our findings
suggest that constitutively active AR variants could be associated
with EMT process. However, these markers are not consistently
associated with EMT. For example, SNAIL confers resistance to
apoptosis to tumor cells exposed to ionizing radiations and
genotoxic drugs, and enables breast cells to become tumor-
initiating cells [30,31,32,33,34].
The expression of mesenchymal markers reported here in the
presence of constitutively active AR variants was not associated
with a downregulation of E-cadherin in our model. The inverse
correlation between N-cadherin upregulation and E-cadherin
downregulation is still debated. Indeed, McKeithen and col-
leagues, and more recently Tiwari and colleagues report a co-
expression of both E- and N-cadherins in tumor cells [35,36]. In
these studies E-cadherin protein displays a different subcellular
localization. Moreover, the reported N-cadherin upregulation
after castration in LNCaP-19 cells is not accompanied by a
decrease of E-cadherin expression in in vitro cell culture [22].
Nevertheless, the expected E-cadherin downregulation in this
model is only observed in orthotopic tumors after castration, but
not in subcutaneous LNCaP-19 tumors, suggesting an important
role of the surrounding prostatic environment for E-cadherin
downregulation [22]. Besides, an inverse correlation between
castration-induced N-cadherin expression and E-cadherin down-
regulation has been documented in LAPC9 and LuCaP35
subcutaneous xenografts models [23,24]. However, this cadherins
switch has not been reported in two studies focusing on human
clinical prostate tumors, from patients with or without androgen
deprivation therapy [22,24].
Further studies are warranted to understand functional conse-
quences of N-cadherin and other mesenchymal markers upregula-
tion in the presence of constitutively active AR variants. N-
cadherin expression is widely associated with tumor progression
notably owing to its role in migration and invasion. Indeed, N-
cadherin favors the migration of cancer cells via cytoskeleton
reorganization and lamellipodia formation [14]. It also promotes
the migration of cancer cells establishing homophilic interactions
with neighboring tissues such as the stromal tissue or endothelium
[37,38]. N-cadherin expression is also associated with survival in
prostate cancer cells and melanoma cells. Indeed, N-cadherin
expression can activate the phosphatidylinositol 3-kinase (PI3K)/
AKT pathway to inactivate pro-apoptotic proteins and to induce
an increase of anti-apoptotic proteins as Bcl-2 [39,40]. Finally, a
recent study showed that N-cadherin could mediate angiogenesis
by inducing monocyte chemoattractant protein-1 (MCP-1)
expression via the PI3K/AKT pathway [41].
There is presently great interest in the mode of action of
constitutively active AR variants in CRPC. In this study, we have
shown for the first time that constitutively active AR variants
induce N-cadherin expression and other mesenchymal markers in
PCa. These findings support the hypothesis that these constitu-
tively active AR variants could contribute to systemic dissemina-
tion of PCa cells, and reinforce the importance to target these AR
variants in PCa.
Figure 4. Upregulation of mesenchymal markers by constitutively active androgen variants in prostate cancer cells. LNCaP cells were
transfected with the ARWT, ARQ640X or AR-V7 expression plasmid or the empty plasmid (C3). A). E-CADHERIN, B). VIMENTIN, C). TWIST1, D). SNAIL and
E). ZEB1 expression levels were analyzed by qRT-PCR at day-9 after transfection. For each sample, expression levels were normalized to PBGD or b-
ACTIN and reported as relative value to LNCaP parental cell line. Values are presented as the mean of DDCt 6 SEM. NS: Not Significant * P,0.05,
**P,0.01 and ***P,0.001. F). Western Blot showing evolution of ZEB1 expression in LNCaP cells overexpressing constitutively active AR variants.
Immunoblot from 100 mg of total protein extracts. b-actin was used as loading control.
doi:10.1371/journal.pone.0063466.g004
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Supporting Information
Figure S1 N-cadherin expression was upregulated in
C4-2B cells in the presence of constitutively active AR
variants. N-cadherin expression was assessed by qRT-PCR in
C4-2B cells overexpressing AR Q640X variant or transfected with
empty plasmid (C3) 4 days after transfection. Parental C4-2B cells
were used as control. N-CADHERIN expression was normalized to
b-ACTIN and calculated using the DDCt method. Results are
presented as the mean of DDCt 6 SEM from three independent
experiments. NS: Not Significant * P,0.05, **P,0.01 and
***P,0.001.
(TIF)
Figure S2 DHT activated AR-FL repressed N-cadherin
expression induced by constitutively active AR variants.
22Rv1 cells were cultured in complete medium supplemented with
100 nM and 1 mM of MDV3100 or DMSO. N-cadherin
expression was analyzed by qRT-PCR four days after and was
normalized to PBGD. The fold change was expressed as relative
values to parental cell line 22Rv1 under normal condition. NS: Not
Significant * P,0.05, **P,0.01 and ***P,0.001.
(TIF)
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